Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Wtihout Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled Trial

Abstrakt

Meningococcal disease occurs with an incidence of 0,2 to 14 per 100 000 population in industrialized countries. Effective vaccines based on capsular polysaccharides for meningococcal serogroups A, C, W-135, and Y are available, but serogroup B capsular polysaccharide is antigenically similar to human neurol cell glycopeptides containig polysialic acid and poorly immunogenic in humans.

Klíčová slova

• serum bacteridicial activity
• membrane vesicle vaccine
• conjugate vaccine
• neisseria.meningitidis
• antibody persistence
• open-label
• children
• disease
• multicenter
• safety